| Name | CLK1/2-IN-3 |
| Description | CLK1/2-IN-3 (Cpd-3) is a potent and selective CLK1 and CLK2 inhibitor with antiproliferative activity and inhibits the activities of CLK1, CLK2, SRPK1, SRPK2, and SRPK3.CLK1/2-IN-3 induces nuclear speckle enlargement, which induces S6K pre-mRNA-selective splicing and subsequent inhibition of cell growth of multiple cancer cell types. cancer cell types cell growth. |
| In vitro | Exposure to CLK1/2-IN-3 (compound 3) at concentrations of 1.1-3.3 μM for 72 hours increases the expression of S6K mRNAs in MDA-MB-468 cells[1].
Significant reduction in the levels of endogenous phosphorylated SR proteins is observed with CLK1/2-IN-3 (5 μM)[1].Anti-proliferative activity is demonstrated by CLK1/2-IN-3 (1-10 μM) with GI50s of 3.4, 2.6, 2.1, 2.5, 2.2, 2.9, 1.5 μM for MDA-MB-468, A549, COLO205, HCT-116, NCI-H23, SW620, COLO320DM cells,respectively[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 3.75 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | CLK2 | CLK1/2-IN-3 | CLK-1/2-IN-3 | CLK1 |
| Inhibitors Related | Ribociclib | Amantadine | Kojic acid | Abemaciclib | Palbociclib | Sodium Oxamate | Seliciclib | Amantadine hydrochloride | FOY 251 | Abemaciclib methanesulfonate | Benzamidine hydrochloride | Dinaciclib |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Bioactive Compounds Library Max | Cell Cycle Compound Library |
United States
